- Home
- ENOV vs ARWR Comparison
ENOV vs ARWR Comparison
Compare ENOV & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENOV
- ARWR
- Stock Information
- Founded
- ENOV 1995
- ARWR 2003
- Country
- ENOV United States
- ARWR United States
- Employees
- ENOV N/A
- ARWR 525
- Industry
- ENOV Fluid Controls
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- ENOV Industrials
- ARWR Health Care
- Exchange
- ENOV Nasdaq
- ARWR Nasdaq
- Market Cap
- ENOV 2.7B
- ARWR 2.7B
- IPO Year
- ENOV 2008
- ARWR 1993
- Fundamental
- Price
- ENOV $45.33
- ARWR $22.25
- Analyst Decision
- ENOV Strong Buy
- ARWR Buy
- Analyst Count
- ENOV 10
- ARWR 12
- Target Price
- ENOV $67.44
- ARWR $42.70
- AVG Volume (30 Days)
- ENOV 539.9K
- ARWR 2.0M
- Earning Date
- ENOV 11-06-2024
- ARWR 02-04-2025
- Dividend Yield
- ENOV N/A
- ARWR N/A
- EPS Growth
- ENOV N/A
- ARWR N/A
- EPS
- ENOV N/A
- ARWR N/A
- Revenue
- ENOV $2,001,668,000.00
- ARWR $3,551,000.00
- Revenue This Year
- ENOV $25.59
- ARWR $4,225.26
- Revenue Next Year
- ENOV $5.97
- ARWR $59.48
- P/E Ratio
- ENOV N/A
- ARWR N/A
- Revenue Growth
- ENOV 20.52
- ARWR N/A
- 52 Week Low
- ENOV $38.27
- ARWR $17.05
- 52 Week High
- ENOV $65.03
- ARWR $39.83
- Technical
- Relative Strength Index (RSI)
- ENOV 46.97
- ARWR 50.44
- Support Level
- ENOV $45.03
- ARWR $21.48
- Resistance Level
- ENOV $47.04
- ARWR $22.47
- Average True Range (ATR)
- ENOV 1.13
- ARWR 1.27
- MACD
- ENOV -0.44
- ARWR -0.23
- Stochastic Oscillator
- ENOV 18.27
- ARWR 12.63
About ENOV Enovis Corporation
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention & Recovery (P&R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention & Recovery segment.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.